Business

Britain says it has offered COVID-19 vaccine to all over-50s By Reuters


2/2

© Reuters. COVID-19 vaccinations in Blackburn

2/2

By Alistair Smout

LONDON (Reuters) – Britain on Monday said it had offered all over-50s a first dose of COVID-19 vaccine, hitting a target to offer injections to all people in its nine highest priority groups by April 15.

Britain has seen one of the world’s quickest vaccine rollouts, behind only Israel in the proportion of its population receiving at least one dose of a COVID-19 shot.

The government said it had offered at least one shot to priority cohorts 1 to 9, which include all adults over 50, the clinically vulnerable, and health and social care workers, ahead of Thursday’s deadline.

“We have now passed another hugely significant milestone in our vaccine programme by offering jabs to everyone in the nine highest risk groups,” Prime Minister Boris Johnson said in a statement.

“We will now move forward with completing essential second doses and making progress towards our target of offering all adults a vaccine by the end of July.”

The success of the vaccine programme has underpinned Johnson’s roadmap out of lockdown, which on Monday saw all shops and outdoor hospitality settings in England reopen.

But Britain has slowed down the pace of first doses, to ensure people in high-priority groups receive a second dose despite lower vaccine supplies in April than March.

Johnson’s office said that the government remained on track to offer all adults a shot by July 31. People in their late 40s are expected to be the next to be invited for shots, though a final decision has not been made, his office said.

READ  Walmart expanding Express Delivery to 1,000 stores to meet demand amid coronavirus crisis

The Joint Committee on Vaccination and Immunisation (JCVI) has previously said that it expects to continue an age-based approach to the rollout, rather than prioritising people based on occupation or other risk factors.

Last week the JCVI also said it advised alternatives to AstraZeneca (NASDAQ:)’s vaccine for those under-30, given a very rare possible side effect of blood clots and the age group’s low risk from COVID-19.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.